Good news, bad news for Cook stent business

Back to TopCommentsE-mailPrintBookmark and Share

Bloomington-based Cook Medical is taking one step forward and one step back with its stent businesses this spring.

Last week, Cook won approval from the U.S. Food and Drug Administration for a new kind of stent to prop open patients' bile ducts. That used to be no big deal, but in recent years, it’s been tougher and tougher to get the OK from the FDA.

The decision gives Cook a new product to offer to the 35,500 Americans each year that receive such a stent, which is designed to relieve symptoms of an obstructed bile duct, according to Today’s Medical Developments, a trade publication.

Cook won approval for its biliary stent in Europe a year ago and has since sold 1,200 of them, according to the trade publication. It sells similar stents, which can be retrieved and replaced by physicians during surgery, for use in the colon, esophagus and duodenum.

“Now clinicians can experience the same precision and control throughout the entire GI tract, from the esophagus to the colon,” said Barry Slowey, global leader of Cook Medical’s Endoscopy division, in a prepared statement.

But in a separate move in late May, the FDA slapped its “deadly” warning on Cook’s recall of its Zilver PTX stent, which props open arteries in the legs and arms to prevent serious blood clots.

That recall, which was initiated by Cook before public action by the FDA, is potentially costly to Cook. Millenium Research Group has estimated that Cook derives $2,750 from each Zilver stent it sells in the United States.

Cook spokesman David McCarty declined to say how many Zilver stents the company has recalled. Since it first hit foreign markets in 2009, the Zilver stent has been deployed in more than 30,000 patients, according to data from Cook.

Millennium estimated that in the United States alone, sales of the Zilver could hit 40,000 per year, generating $110 million in annual revenue. The Zilver, which is the first stent covered with an inflammation-reducing drug, has been selling in Europe and other foreign markets since 2009. Cook introduced it to the U.S. market in December 2012.

The Zilver recall did not affect stents that were already placed in patients because a small number of them broke off from the catheter delivering them into the patients during surgery. But the problem could cause thrombosis and even death, according to the FDA.

McCarty said all the Zilver stents sold from Dec. 13 to April 16 have now been called in from the field and new stents have been manufactured at Cook's plant in Limerick, Ireland. Cook is waiting for regulatory approval to send out the replacement Zilver stents.

“We're preparing to return to market as quickly as possible,” he wrote in an email. “Lots of patients out there needing this device and lots of doctors asking when it will be back.”


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. How can any company that has the cash and other assets be allowed to simply foreclose and not pay the debt? Simon, pay the debt and sell the property yourself. Don't just stiff the bank with the loan and require them to find a buyer.

  2. If you only knew....

  3. The proposal is structured in such a way that a private company (who has competitors in the marketplace) has struck a deal to get "financing" through utility ratepayers via IPL. Competitors to BlueIndy are at disadvantage now. The story isn't "how green can we be" but how creative "financing" through captive ratepayers benefits a company whose proposal should sink or float in the competitive marketplace without customer funding. If it was a great idea there would be financing available. IBJ needs to be doing a story on the utility ratemaking piece of this (which is pretty complicated) but instead it suggests that folks are whining about paying for being green.

  4. The facts contained in your post make your position so much more credible than those based on sheer emotion. Thanks for enlightening us.

  5. Please consider a couple of economic realities: First, retail is more consolidated now than it was when malls like this were built. There used to be many department stores. Now, in essence, there is one--Macy's. Right off, you've eliminated the need for multiple anchor stores in malls. And in-line retailers have consolidated or folded or have stopped building new stores because so much of their business is now online. The Limited, for example, Next, malls are closing all over the country, even some of the former gems are now derelict.Times change. And finally, as the income level of any particular area declines, so do the retail offerings. Sad, but true.